Up‐regulation of the long non‐coding RNAs DSCAM‐AS1 and MANCR is a potential diagnostic marker for breast carcinoma

Breast cancer (BC) is one of the most common malignancies among women in the world. There is a global attempt to diagnose breast cancer (BC) as early as possible. Long non-coding RNAs (lncRNAs) are emerging as novel targets and biomarkers for BC diagnosis and prognosis. Aberrant expression of lncRNAs is associated with BC development, making them a potential tumor marker for BC. To investigate this possibility, we determined the expression levels of Down Syndrome Cell Adhesion Molecule-Antisense RNA-1 (DSCAM-AS1) and Mitotically-Associated Long Non-Coding RNA (MANCR) lncRNAs in BC tissues. This case-control study was included 50 paired tumor and adjacent non-tumor tissues from female BC patients. The total RNA was isolated and the expression levels of MANCR and DSCAM-AS1 lncRNAs were assessed using quantitative real-time reverse transcription-PCR. Potential correlations between lncRNA levels and clinicopathological characteristics were also analyzed. DSCAM-AS1 and MANCR lncRNAs were significantly up-regulated in BC tumor tissues compared with the adjacent non-tumor tissues. We also found the significant up-regulation of DSCAM-AS1 in advanced tumor-node-metastasis stage (TNM III) of BC tumor tissues. Furthermore, the expression of DSCAM-AS1 and MANCR in HER-2 positive patients was significantly higher than HER-2 negative affected individuals. Receiver operating characteristic curve analysis showed a satisfactory diagnostic efficacy (P-value < 0.0001) which means that DSCAM-AS1 and MANCR lncRNAs can potentially serve as a biomarker. The present study might provide further approval for the clinical diagnostic significance of DSCAM-AS1 and MANCR lncRNAs that their high expressions were associated with aggressive clinical parameters of BC. This article is protected by copyright. All rights reserved.